e-learning
resources
European Respiratory Review
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dual endothelin receptor antagonism: setting standards in PAH
Humbert M.
Source:
Eur Respir Rev 2008; 17: 13-18
Journal Issue:
August 2007 - 16 (102)
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Humbert M.. Dual endothelin receptor antagonism: setting standards in PAH. Eur Respir Rev 2008; 17: 13-18
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Endothelin: setting the scene in PAH
Source: Eur Respir Rev 2008; 17: 3-7
Year: 2007
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Single centre experience with endothelin receptor blockade in pulmonary hypertension
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011
Inhalation of endothelin receptor blockers in pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Selective
versus
non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005
Dual endothelin receptor blockade: advances in pulmonary disease
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 204s
Year: 2005
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: 1007-1010
Year: 2004
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010
The use of combination therapy in pulmonary arterial hypertension: new developments
Source: Eur Respir Rev 2009; 18: 148-153
Year: 2009
Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Bosentan therapy for portopulmonary hypertension
Source: Eur Respir J 2005; 25: 502-508
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept